Cannabix and AlcoPro Enter MOU for Marijuana
Breathalyzer Marketing
Vancouver, British Columbia, Canada -- January 24, 2025 --
InvestorsHub NewsWire -- Cannabix Technologies Inc. (CSE:
BLO) (OTC
PINK: BLOZF) (Frankfurt: 8CT) (the "Company" or "Cannabix")
developer of marijuana and alcohol breath testing devices is
pleased to report that it has entered a memorandum of understanding
("MOU") with AlcoPro Inc. ("AlcoPro") of Knoxville, TN, to begin
collaborating on marketing efforts for the Cannabix Marijuana
Breathalyzer ("CMB") technology in the United States. In the
short-term, AlcoPro will include the CMB hardware in its upcoming
2025 product catalogue, mailed to over 70,000 businesses in U.S.
and globally. AlcoPro is a well-established distributor and leading
supplier of drug and alcohol testing instruments, kits, and
supplies for professional use, since 1982.
The
objective of the MOU is to establish preliminary marketing exposure
of the CMB to AlcoPro customers, gauge interest and work towards a
future distribution agreement. Cannabix recently upgraded its
Breath Collection Unit ("BCU") – a critical hardware tool used for
portable collection of delta-9 THC in breath (image below).
Cannabix is quickly advancing its marijuana breathalyzer
technology, with key validation work well underway in the United
States.
Cannabix Breath Collection Unit ("BCU") with
Breath Cartridge technology.
Rav Mlait,
CEO of Cannabix stated, "We are very pleased to be building a
relationship with AlcoPro to begin preliminary marketing of our
technology. The Company continues to advance its marijuana
breathalyzer technology with key scientific validations and testing
which are well underway."
Brian
Terry, Director of Business Development of AlcoPro stated, "We are
thrilled to establish a relationship with Cannabix Technologies,
broadening our focus from providing physical testing tools to
embracing innovative technologies that address the growing need for
accurate and reliable THC detection. As workplace safety challenges
evolve, it's critical to stay at the forefront of solutions that
proactively mitigate risks and ensure a safer environment for
employees."
About AlcoPro, Inc.
Since
1982, AlcoPro has been a trusted leader in drug and alcohol testing
solutions for employers, healthcare professionals, law enforcement,
and substance abuse specialists. Known for reliable instruments
like market-leading breathalyzers, AlcoPro also offers innovative
online training with interactive tools to enhance knowledge
retention. With a comprehensive product catalog, easy online
ordering, and expert support, AlcoPro makes workplace testing
simple, accurate, and professional. Learn more at
www.AlcoPro.com.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol
breathalyzer technologies for law enforcement, workplaces and
laboratories. Cannabix is developing delta-9 THC and alcohol
screening devices. Delta-9 THC is the primary psychoactive
ingredient in cannabis. Breath testing for delta-9 THC would allow
employers and law enforcement to identify recent marijuana
use. Cannabix is the developer of its Breath Logix Series of breath
alcohol detection devices for employers and a range of other
settings.
We seek
Safe Harbor.
On behalf of the
Board of Directors
"Rav Mlait"
CEO
Cannabix Technologies
Inc.
For further information,
contact the Company at info@cannabixtechnologies.com
Cautionary Statement
Regarding Forward-Looking Statements
This news release contains certain
"forward-looking statements" within the meaning of such statements
under applicable securities law. Forward-looking statements are
frequently characterized by words such as "anticipates," "plan,"
"continue," "expect," "project," "intend," "believe," "anticipate,"
"estimate," "may," "will," "potential," "proposed," "positioned"
and other similar words, or statements that certain events or
conditions "may" or "will" occur. Forward-looking statements in
this news release include, but are not limited to, statements
relating to: the achievement of any or all of the goals and aims of
an "MOU" or partnerships as described in this news release; final
development of a commercial or prototype product(s); the successful
trial or pilot of company technologies; the commercialization of
the Company's products; the negotiation and potential entry into
additional agreements with existing and new partners; and the
completion of future financings. There are numerous risks and
uncertainties that could cause actual results and the Company's
plans and objectives to differ materially from those expressed in
the forward-looking information. Important factors that could cause
actual results to differ materially from those expressed in the
forward-looking information include (but are note limited to):
adverse market conditions; risks regarding protection of
proprietary technology; the ability of the Company to complete
future financings; the ability of the Company to develop and market
its future product; risks regarding government regulation, managing
and maintaining growth, the effect of adverse publicity,
litigation, competition; that partners may not complete all or any
of the milestones as contemplated strategic partnership agreements;
that the CSE may not approve the issuance of the securities; that
the Company's development of breathalyzer technology will provide
any benefit to the Company; there is no assurance that any proposed
new products will be built, will be successful in beta testing or
clinical trials; there is no assurance that the Company will enter
into any partnerships to advance any of its corporate initiatives
or technologies; there is no assurance that any "patent pending" or
"provisional patents" technologies licensed by the Company or owned
by the Company will receive patent status by regulatory
authorities; the Company is not currently selling breathalyzers and
there is no assurance that the Company ever will; and other factors
beyond the control of the Company. Actual results and future events
could differ materially from those anticipated in such information.
These and all subsequent written and oral forward-looking
information are based on estimates and opinions of management on
the dates they are made and are expressly qualified in their
entirety by this notice. Except as required by law, the Company
does not intend to update these forward-looking
statements.
The CSE has not reviewed and does not accept
responsibility for the adequacy or accuracy of this
release.
501-3292 Production Way, Burnaby, B.C., V5A 4R4
Phone: (604) 551-7831 Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix Technologies (CSE:BLO)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Cannabix Technologies (CSE:BLO)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
